Abstract
For sustained growth, tumors are dependent upon neovascularization to feed their massive demand for nutrients and oxygen. Cancer cells produce growth factors and activators that stimulate vessels in the surrounding tissue to form a new circulatory network around the tumor. Therapies aimed at reducing the blood flow to the cancer cells can slow down tumor growth and reduce metastasis. This review describes novel anti-angiogenic agents, including antibodies directed against vascular growth factors and angiotensin II, pharmaceutical compounds and natural metabolites derived from plants and microorganisms. The relevant patents are discussed. These agents may become valuable anti-cancer therapeutics in the future, as a supplement to chemo- and radiation-therapy.
Keywords: Angiogenesis, antibiotics, antibody therapy, angiotensin-converting enzyme inhibitors, angiotensin II receptor 1 antagonists, combination therapy, matrix metalloproteinases, opioids, polyphenols, simmondsins
Recent Patents on Anti-Cancer Drug Discovery
Title: Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives
Volume: 4 Issue: 2
Author(s): Boel De Paepe
Affiliation:
Keywords: Angiogenesis, antibiotics, antibody therapy, angiotensin-converting enzyme inhibitors, angiotensin II receptor 1 antagonists, combination therapy, matrix metalloproteinases, opioids, polyphenols, simmondsins
Abstract: For sustained growth, tumors are dependent upon neovascularization to feed their massive demand for nutrients and oxygen. Cancer cells produce growth factors and activators that stimulate vessels in the surrounding tissue to form a new circulatory network around the tumor. Therapies aimed at reducing the blood flow to the cancer cells can slow down tumor growth and reduce metastasis. This review describes novel anti-angiogenic agents, including antibodies directed against vascular growth factors and angiotensin II, pharmaceutical compounds and natural metabolites derived from plants and microorganisms. The relevant patents are discussed. These agents may become valuable anti-cancer therapeutics in the future, as a supplement to chemo- and radiation-therapy.
Export Options
About this article
Cite this article as:
De Paepe Boel, Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (2) . https://dx.doi.org/10.2174/157489209788452821
DOI https://dx.doi.org/10.2174/157489209788452821 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cigarette Smoking and Hypertension
Current Pharmaceutical Design Neutrophil MiRNA-128-3p is Decreased During Active Phase of Granulomatosis with Polyangiitis
Current Genomics Generation of Bispecific Antibodies by Fc Heterodimerization and their Application
Current Pharmaceutical Biotechnology Anti-Tumor Necrosis Factor Blocking Agents in the Treatment of Systemic Vasculitis
Current Immunology Reviews (Discontinued) Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Angiogenesis Inhibition in the Treatment of Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Transposon-Based Engineering of Clinical-Grade T Cells for Cancer Therapy
Current Drug Therapy DIMming Ovarian Cancer Growth
Current Drug Targets Microbial Polysaccharides and their Derivatives as Current and Prospective Pharmaceuticals
Current Pharmaceutical Design Does Hepatic Steatosis Affect Drug Metabolizing Enzymes in the Liver?
Current Drug Metabolism Titanium Dioxide Nanoparticles: a Risk for Human Health?
Mini-Reviews in Medicinal Chemistry Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals